In vitro susceptibility of mycobacterium bovis against moxifloxacin Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Characterization of drug susceptibility of nontuberculous mycobacteria of M.chelonae and M.fortuitum complexes. Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
In vitro susceptibility of M. avium against protionamide Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017
The spectrum of drug susceptibility of slow-growing nontuberculous mycobacteria (MAC, M. kansasii, M. xenopi) Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
Detection of Mycobacterium tuberculosis in children during complex antimycobacterial therapy Source: Annual Congress 2009 - Genetics of lung diseases Year: 2009
Clinical relevance of Mycobacterium malmoense isolation in the Netherlands Source: Eur Respir J 2009; 34: 926-931 Year: 2009
Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012
Investigation of the inhibition of adherence of Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis (MTB) to the respiratory mucosa Source: Eur Respir J 2001; 18: Suppl. 33, 480s Year: 2001
In vitro susceptibility of non-tuberculous mycobacterial strains against moxifloxacin Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016
Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017
In-vitro and in-vivo activity of rifampicin and rifabutin against multi-drug-resistant strains of mycobacterium tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
In vitro susceptibility testing and totally drug-resistant tuberculosis Source: Eur Respir J 2013; 42: 291-292 Year: 2013
In vitro susceptibility testing and totally drug-resistant tuberculosis Source: Eur Respir J 2013; 42: 292 Year: 2013
Colorimetric assays for rapid drug susceptibility testing of Mycobacterium tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 167s Year: 2003
Discriminating active from latent tuberculosis by Mycobacterium tuberculosis (MTB)-peptide specific immunoresponses Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008
Mycobacterium abscessus activates cross-resistance following antibiotic exposure Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020